Truqap (capivasertib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00082228.PDF. Revised October 2025. Accessed April 2026.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations Biomarkers Cancer types Therapies